Overview

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) or Non-IPF Progressive Pulmonary Fibrosis

Status:
Not yet recruiting

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with ILDs manifesting PPF or with IPF.

Phase:

Phase 2

Details

Lead Sponsor:

Cumberland Pharmaceuticals

Treatments:

Ifetroban